deposiston and Growth-Disorders

Continuous intravenous insulin infusion tests, accompanied by growth hormone determination, were applied to 40 girls of tall growth whose final lengths were predicted to be in excess of 181 cm. The girls were aged between nine and half and 14 years and one month, all of them being in the premenarchic phase. The tests were conducted prior to and following at least one year of Deposiston therapy (oestrogen/gestagen). - Really effective inhibition of growth (7.4 +/- 0.6 cm) was obtained only from five girls, aged between nine years and ten months and eleven years, in whom basal secretion of HGH was lower with significance than that of the whole group, with their stimulation reaction being fully retained. Secretion of somatotropic hormone (STH) of the other girls remained unaffected, prior to and following treatment. The weekly oestrogen dose of 1 mg was relatively low, when compared to propositions made by other authors, but it seemed to be justified by the average reduction in expected final body length obtained for the probands reviewed (5.4 +/- 2.0 cm).. Continuous intravenous insulin infusion tests, accompanied by growth hormone determination, were applied to 40 tall girls whose final heights were predicted to be in excess of 181 cm. The girls, ages 9 1/2 to 14 years 1 month were all premenstrual. Tests were conducted prior to and following at least 1 year of Deposiston therapy (estrogen gestagen). Truly effective inhibition of growth (7.4 + or - 0.6 cm) was seen only in 5 girls ages 9 years 10 months and 11 years in whom basal secretion of HGH was lower than the rest of the group. Their stimulation reaction was fully retained. Secretion of somatotropic hormone of the other girls remained unaffected prior to and following treatment. The weekly estrogen dose of 4 mg was relatively low when compared to administrations reported by other authors but it seemed justified by the average reduction in expected final body height obtained for the subjects reviewed (5.4 + or - 2.0 cm). (Author's modified)

Topics: Adolescent; Body Height; Child; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; Female; Growth Disorders; Growth Hormone; Humans; Infusions, Parenteral; Insulin; Norethindrone